EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure
Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.

New Molecule

11 New

New Formulation

1 New

New Indication

2 New

Markings
Shape
Form
Color 1
Color 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in